We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
There isn’t enough historical data to display yet.
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $61.4 · 15 analysts
Stored first · Google News · Yahoo Finance (English)
BrightSpring Health Services, Inc. Stock 12‑Month Price Target Raised to $76.76, Implies 10% Upside - TradingView
BrightSpring Health Services, Inc. Stock 12‑Month Price Target Raised to $76.76, Implies 10% Upside TradingView
Morgan Stanley Raises Price Target on BrightSpring Health Services to $80 From $71, Keeps Overweight Rating
American Express, Biogen upgraded: Wall Street's top analyst calls
Guggenheim Initiates Coverage on BrightSpring Health Services With Buy Rating, $81 Price Target - marketscreener.com
Guggenheim Initiates Coverage on BrightSpring Health Services With Buy Rating, $81 Price Target marketscreener.com
BrightSpring Health Services (BTSG) Q1 2026 Earnings Call Transcript - Fortune
BrightSpring Health Services (BTSG) Q1 2026 Earnings Call Transcript Fortune
BrightSpring Health Services (BTSG) Could Be 1% Overvalued Following Strong Revenue Growth - simplywall.st
BrightSpring Health Services (BTSG) Could Be 1% Overvalued Following Strong Revenue Growth simplywall.st
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 31. | After market close (AMC) | $0.39 | — | — | $3.67B | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.14 | — | — | $2.88B | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.18 | — | — | $7.33B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.14 | — | — | $4.72B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 07. | Morgan Stanley | — | Maintain | Overweight → Overweight | — | Morgan Stanley: Overweight |
| 2026. 05. 05. | Mizuho | — | Maintain | Outperform → Outperform | — | Mizuho: Outperform |
| 2026. 05. 05. | Wells Fargo | — | Maintain | Overweight → Overweight | — | Wells Fargo: Overweight |
| 2026. 05. 05. | TD Cowen | — | Maintain | Buy → Buy | — | TD Cowen: Buy |
| 2026. 05. 04. | Keybanc | — | Maintain | Overweight → Overweight | — | Keybanc: Overweight |
| 2026. 05. 04. | Stephens & Co. | — | Maintain | Overweight → Overweight | — | Stephens & Co.: Overweight |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.